Cargando…

Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis

Transthyretin (TTR), the precursor protein for amyloidogenic TTR (ATTR) amyloidosis, forms tetramers and escapes glomerular filtration by binding with thyroxine and retinol-binding protein. However, variant TTRs are unstable as tetramers, so monomeric TTR has become the precursor protein of amyloid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsushita, Hiroaki, Misumi, Yohei, Masuda, Teruaki, Okada, Masamitsu, Inoue, Fumika, Ueda, Mitsuharu, Ando, Yukio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326616/ https://www.ncbi.nlm.nih.gov/pubmed/35893595 http://dx.doi.org/10.3390/pathophysiology29030025

Ejemplares similares

Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis
por: Okada, Masamitsu, et al.
Publicado: (2020)

Glavonoid, a possible supplement for prevention of ATTR amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2021)

New simple and quick method to analyze serum variant transthyretins: direct MALDI method for the screening of hereditary transthyretin amyloidosis
por: Nomura, Toshiya, et al.
Publicado: (2019)

Amyloid fibril formation is suppressed in microgravity
por: Matsushita, Hiroaki, et al.
Publicado: (2020)

Recent advances in transthyretin amyloidosis therapy
por: Ueda, Mitsuharu, et al.
Publicado: (2014)

Non‐Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis
por: Hirakawa, Kyoko, et al.
Publicado: (2018)

Amyloid fibril composition within hereditary Val30Met (p. Val50Met) transthyretin amyloidosis families
por: Suhr, Ole Bernt, et al.
Publicado: (2019)

Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Waddington-Cruz, Márcia, et al.
Publicado: (2021)

Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening
por: Tsuda, Yukimoto, et al.
Publicado: (2018)

Hereditary ATTR Amyloidosis with Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S)
por: Nakase, Taku, et al.
Publicado: (2019)

Amyloid fibril composition type is consistent over time in patients with Val30Met (p.Val50Met) transthyretin amyloidosis
por: Anan, Intissar, et al.
Publicado: (2022)

Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin
por: Suenaga, Genki, et al.
Publicado: (2017)

The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis
por: Vera-Llonch, Montserrat, et al.
Publicado: (2021)

Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy
por: Dardiotis, Efthimios, et al.
Publicado: (2023)

Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden
por: González-Moreno, Juan, et al.
Publicado: (2021)

Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features
por: Pozsonyi, Zoltán, et al.
Publicado: (2021)

Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
por: Merlini, Giampaolo, et al.
Publicado: (2013)

Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy
por: Magliano, Lorenza, et al.
Publicado: (2021)

Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen
por: Coelho, Teresa, et al.
Publicado: (2022)

Widespread Cardiac and Vasomotor Autonomic Dysfunction in Non-Val30Met Hereditary Transthyretin Amyloidosis
por: Koike, Haruki, et al.
Publicado: (2018)

Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca
por: Cisneros-Barroso, E., et al.
Publicado: (2023)

Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal
por: Ando, Yukio, et al.
Publicado: (2023)

A novel TTR mutation (p.Ala65Val) underlying late-onset hereditary transthyretin (ATTRv) amyloidosis with mixed cardiac and neuropathic phenotype: a case report
por: Thimm, Andreas, et al.
Publicado: (2022)

Long-term surgical results of trabeculectomy for secondary glaucoma in Val30Met hereditary transthyretin amyloidosis
por: Kitahara, Junya, et al.
Publicado: (2023)

The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data
por: Reddy, Sheila R., et al.
Publicado: (2020)

Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis
por: Zampino, Serena, et al.
Publicado: (2023)

Late-Onset Hereditary Transthyretin Amyloidosis Val30Met in an Elderly Person in a Non-Endemic Area
por: Wang, Shun, et al.
Publicado: (2022)

Suture trabeculotomy ab interno for secondary glaucoma in Japanese patients with Val30Met hereditary transthyretin amyloidosis
por: Kawaji, Takahiro, et al.
Publicado: (2022)

Case Report: Hereditary transthyretin (ATTRv) amyloidosis: The p.G103R mutation of the transthyretin gene in a Han Chinese family is associated with vitreous hemorrhage
por: Shen, Junhui, et al.
Publicado: (2022)

Vasculopathy in transthyretin Val30Met familial amyloid polyneuropathy
por: Koike, Haruki, et al.
Publicado: (2015)

Evolving landscape in the management of transthyretin amyloidosis
por: Hawkins, Philip N., et al.
Publicado: (2015)

Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis
por: Damy, Thibaud, et al.
Publicado: (2015)

Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects
por: Russo, Massimo, et al.
Publicado: (2020)

Current Evidence Supporting the Role of Immune Response in ATTRv Amyloidosis
por: Plantone, Domenico, et al.
Publicado: (2023)

Temporal Change in Longitudinal Strain After Domino Liver Transplantation With Liver Grafts Explanted From Patients With Hereditary Amyloidogenic Transthyretin Amyloidosis
por: Usuku, Hiroki, et al.
Publicado: (2020)

Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy
por: Inoue, Yasuteru, et al.
Publicado: (2021)

Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy
por: Gundapaneni, B. K., et al.
Publicado: (2017)

Wild-type Transthyretin Amyloidosis with Diffuse Alveolar-septal Amyloidosis Diagnosed by a Transbronchial Lung Biopsy
por: Ishida, Masaki, et al.
Publicado: (2022)

Ocular findings in patients with acquired ATTRv amyloidosis following domino liver transplantation
por: Kitahara, Junya, et al.
Publicado: (2023)

The Val142Ile transthyretin cardiac amyloidosis: more than an Afro-American pathogenic variant
por: Perfetto, Federico, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_88ee51pujq2ia0a960pp0huq9h